Search
Terazosin
go.drugbank.com/drugs/DB01162ApprovedInvestigationalTerazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label] . Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing rela...
Categories: P-glycoprotein inhibitors, Adrenergic alpha-1 Receptor AntagonistsCyclizine
go.drugbank.com/drugs/DB01176ApprovedWithdrawnA histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsClindamycin
go.drugbank.com/drugs/DB01190ApprovedInvestigationalVet approvedClindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity tha...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: Clindacin PAcebutolol
go.drugbank.com/drugs/DB01193ApprovedInvestigationalA cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
Categories: Adrenergic beta-1 Receptor Antagonists, P-glycoprotein substratesKetamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedKetamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories.
Categories: NMDA Receptor Antagonists, Cytochrome P-450 SubstratesQuetiapine
go.drugbank.com/drugs/DB01224ApprovedInvestigationalInitially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of a...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesLevacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnLevacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT inte...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSaquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalSaquinavir is an HIV-1 protease inhibitor used in combination with ritonavir and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the ...
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsBepridil
go.drugbank.com/drugs/DB01244ApprovedWithdrawnA long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activi...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalLapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. … It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Categories: Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors, P-glycoprotein inhibitors